James K. McCloskey, MD

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.

James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.

James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.

Drs Gerds and McCloskey discuss JAK inhibitors for patients with myelofibrosis, tips for symptom management, and emerging myelofibrosis research.

Dr McCloskey highlights challenges in adverse event management and discusses unmet needs in the treatment of patients with leukemia.

James K. McCloskey, MD, provides an overview of key takeaways from recent studies presented at the 2023 ASH Annual Meeting in leukemia.

An expert on leukemia provides comprehensive insights on the subgroup analysis of the phase 3 PhALLCON study of ponatinib in Ph+ acute lymphoblastic leukemia.

Focusing on chronic myeloid leukemia, James K. McCloskey, MD, reviews the long-term results of the OPTIC trial presented at ASH 2023.

Following ASH 2023, a hematologist-oncologist discusses recent updates on approved and emerging therapies for patients with leukemia, highlighting the TRANSFORM-1 trial looking at navitoclax plus ruxolitinib.

James K. McCloskey, MD, a specialist in leukemia, discusses how the treatment landscape has changed in recent years.

James K. McCloskey, MD, discusses the potential for machine learning to replace flow cytometry analyses in patients with hematologic neoplasms.